The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Dactinomycin Market Research Report 2024
Synopsis
Dactinomycin is a mixture of Streptomyces chrysomallus, mainly composed of C1, C2, C3 and D.Red or orange-yellow crystalline powder of madder.Soluble in ethanol, acetone and benzene.Its effect is similar to that of actinomycin, and it has a wide antitumor spectrum.In addition, also has the strong resistance bacteria, fungi and viruses.It is mainly used for Hodgkin's disease, nephroblastoma and leukemia in children.The toxic and side effects are similar to those of actinomycin, mainly myelosuppression and gastrointestinal reactions.Advanced malignant tumors, low red and white blood cells and pregnant women are contraindicated.
The global Dactinomycin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Dactinomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dactinomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Dactinomycin in Alkylating Agent is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Dactinomycin include AstraZeneca, GSK, Recordati Rare Diseases, Lundbeck, Merck, Prasco Laboratories, X-GEN Pharmaceuticals, Mylan Institutional and Bedford Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dactinomycin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dactinomycin.
Report Scope
The Dactinomycin market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dactinomycin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dactinomycin companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
GSK
Recordati Rare Diseases
Lundbeck
Merck
Prasco Laboratories
X-GEN Pharmaceuticals
Mylan Institutional
Bedford Pharmaceuticals
HISUN
Hainan Jinrui Pharmaceutical
Qilu Pharmaceutical
Shanghai Zhongke Pharmaceutical
Shanghai Xinya Pharmaceutical
Nantong Xinhe Biotechnology
Segment by Type
Injection
Implants
Segment by Application
Alkylating Agent
Hormone
Plant Medicine
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dactinomycin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Dactinomycin is a mixture of Streptomyces chrysomallus, mainly composed of C1, C2, C3 and D.Red or orange-yellow crystalline powder of madder.Soluble in ethanol, acetone and benzene.Its effect is similar to that of actinomycin, and it has a wide antitumor spectrum.In addition, also has the strong resistance bacteria, fungi and viruses.It is mainly used for Hodgkin's disease, nephroblastoma and leukemia in children.The toxic and side effects are similar to those of actinomycin, mainly myelosuppression and gastrointestinal reactions.Advanced malignant tumors, low red and white blood cells and pregnant women are contraindicated.
The global Dactinomycin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Dactinomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dactinomycin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Dactinomycin in Alkylating Agent is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Dactinomycin include AstraZeneca, GSK, Recordati Rare Diseases, Lundbeck, Merck, Prasco Laboratories, X-GEN Pharmaceuticals, Mylan Institutional and Bedford Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dactinomycin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dactinomycin.
Report Scope
The Dactinomycin market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dactinomycin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dactinomycin companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
GSK
Recordati Rare Diseases
Lundbeck
Merck
Prasco Laboratories
X-GEN Pharmaceuticals
Mylan Institutional
Bedford Pharmaceuticals
HISUN
Hainan Jinrui Pharmaceutical
Qilu Pharmaceutical
Shanghai Zhongke Pharmaceutical
Shanghai Xinya Pharmaceutical
Nantong Xinhe Biotechnology
Segment by Type
Injection
Implants
Segment by Application
Alkylating Agent
Hormone
Plant Medicine
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dactinomycin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dactinomycin Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Injection
1.2.3 Implants
1.3 Market by Application
1.3.1 Global Dactinomycin Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Alkylating Agent
1.3.3 Hormone
1.3.4 Plant Medicine
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dactinomycin Market Perspective (2019-2030)
2.2 Dactinomycin Growth Trends by Region
2.2.1 Global Dactinomycin Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Dactinomycin Historic Market Size by Region (2019-2024)
2.2.3 Dactinomycin Forecasted Market Size by Region (2025-2030)
2.3 Dactinomycin Market Dynamics
2.3.1 Dactinomycin Industry Trends
2.3.2 Dactinomycin Market Drivers
2.3.3 Dactinomycin Market Challenges
2.3.4 Dactinomycin Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dactinomycin Players by Revenue
3.1.1 Global Top Dactinomycin Players by Revenue (2019-2024)
3.1.2 Global Dactinomycin Revenue Market Share by Players (2019-2024)
3.2 Global Dactinomycin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dactinomycin Revenue
3.4 Global Dactinomycin Market Concentration Ratio
3.4.1 Global Dactinomycin Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dactinomycin Revenue in 2023
3.5 Dactinomycin Key Players Head office and Area Served
3.6 Key Players Dactinomycin Product Solution and Service
3.7 Date of Enter into Dactinomycin Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dactinomycin Breakdown Data by Type
4.1 Global Dactinomycin Historic Market Size by Type (2019-2024)
4.2 Global Dactinomycin Forecasted Market Size by Type (2025-2030)
5 Dactinomycin Breakdown Data by Application
5.1 Global Dactinomycin Historic Market Size by Application (2019-2024)
5.2 Global Dactinomycin Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Dactinomycin Market Size (2019-2030)
6.2 North America Dactinomycin Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Dactinomycin Market Size by Country (2019-2024)
6.4 North America Dactinomycin Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dactinomycin Market Size (2019-2030)
7.2 Europe Dactinomycin Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Dactinomycin Market Size by Country (2019-2024)
7.4 Europe Dactinomycin Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dactinomycin Market Size (2019-2030)
8.2 Asia-Pacific Dactinomycin Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Dactinomycin Market Size by Region (2019-2024)
8.4 Asia-Pacific Dactinomycin Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dactinomycin Market Size (2019-2030)
9.2 Latin America Dactinomycin Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Dactinomycin Market Size by Country (2019-2024)
9.4 Latin America Dactinomycin Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dactinomycin Market Size (2019-2030)
10.2 Middle East & Africa Dactinomycin Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Dactinomycin Market Size by Country (2019-2024)
10.4 Middle East & Africa Dactinomycin Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Dactinomycin Introduction
11.1.4 AstraZeneca Revenue in Dactinomycin Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Dactinomycin Introduction
11.2.4 GSK Revenue in Dactinomycin Business (2019-2024)
11.2.5 GSK Recent Development
11.3 Recordati Rare Diseases
11.3.1 Recordati Rare Diseases Company Detail
11.3.2 Recordati Rare Diseases Business Overview
11.3.3 Recordati Rare Diseases Dactinomycin Introduction
11.3.4 Recordati Rare Diseases Revenue in Dactinomycin Business (2019-2024)
11.3.5 Recordati Rare Diseases Recent Development
11.4 Lundbeck
11.4.1 Lundbeck Company Detail
11.4.2 Lundbeck Business Overview
11.4.3 Lundbeck Dactinomycin Introduction
11.4.4 Lundbeck Revenue in Dactinomycin Business (2019-2024)
11.4.5 Lundbeck Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Dactinomycin Introduction
11.5.4 Merck Revenue in Dactinomycin Business (2019-2024)
11.5.5 Merck Recent Development
11.6 Prasco Laboratories
11.6.1 Prasco Laboratories Company Detail
11.6.2 Prasco Laboratories Business Overview
11.6.3 Prasco Laboratories Dactinomycin Introduction
11.6.4 Prasco Laboratories Revenue in Dactinomycin Business (2019-2024)
11.6.5 Prasco Laboratories Recent Development
11.7 X-GEN Pharmaceuticals
11.7.1 X-GEN Pharmaceuticals Company Detail
11.7.2 X-GEN Pharmaceuticals Business Overview
11.7.3 X-GEN Pharmaceuticals Dactinomycin Introduction
11.7.4 X-GEN Pharmaceuticals Revenue in Dactinomycin Business (2019-2024)
11.7.5 X-GEN Pharmaceuticals Recent Development
11.8 Mylan Institutional
11.8.1 Mylan Institutional Company Detail
11.8.2 Mylan Institutional Business Overview
11.8.3 Mylan Institutional Dactinomycin Introduction
11.8.4 Mylan Institutional Revenue in Dactinomycin Business (2019-2024)
11.8.5 Mylan Institutional Recent Development
11.9 Bedford Pharmaceuticals
11.9.1 Bedford Pharmaceuticals Company Detail
11.9.2 Bedford Pharmaceuticals Business Overview
11.9.3 Bedford Pharmaceuticals Dactinomycin Introduction
11.9.4 Bedford Pharmaceuticals Revenue in Dactinomycin Business (2019-2024)
11.9.5 Bedford Pharmaceuticals Recent Development
11.10 HISUN
11.10.1 HISUN Company Detail
11.10.2 HISUN Business Overview
11.10.3 HISUN Dactinomycin Introduction
11.10.4 HISUN Revenue in Dactinomycin Business (2019-2024)
11.10.5 HISUN Recent Development
11.11 Hainan Jinrui Pharmaceutical
11.11.1 Hainan Jinrui Pharmaceutical Company Detail
11.11.2 Hainan Jinrui Pharmaceutical Business Overview
11.11.3 Hainan Jinrui Pharmaceutical Dactinomycin Introduction
11.11.4 Hainan Jinrui Pharmaceutical Revenue in Dactinomycin Business (2019-2024)
11.11.5 Hainan Jinrui Pharmaceutical Recent Development
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Company Detail
11.12.2 Qilu Pharmaceutical Business Overview
11.12.3 Qilu Pharmaceutical Dactinomycin Introduction
11.12.4 Qilu Pharmaceutical Revenue in Dactinomycin Business (2019-2024)
11.12.5 Qilu Pharmaceutical Recent Development
11.13 Shanghai Zhongke Pharmaceutical
11.13.1 Shanghai Zhongke Pharmaceutical Company Detail
11.13.2 Shanghai Zhongke Pharmaceutical Business Overview
11.13.3 Shanghai Zhongke Pharmaceutical Dactinomycin Introduction
11.13.4 Shanghai Zhongke Pharmaceutical Revenue in Dactinomycin Business (2019-2024)
11.13.5 Shanghai Zhongke Pharmaceutical Recent Development
11.14 Shanghai Xinya Pharmaceutical
11.14.1 Shanghai Xinya Pharmaceutical Company Detail
11.14.2 Shanghai Xinya Pharmaceutical Business Overview
11.14.3 Shanghai Xinya Pharmaceutical Dactinomycin Introduction
11.14.4 Shanghai Xinya Pharmaceutical Revenue in Dactinomycin Business (2019-2024)
11.14.5 Shanghai Xinya Pharmaceutical Recent Development
11.15 Nantong Xinhe Biotechnology
11.15.1 Nantong Xinhe Biotechnology Company Detail
11.15.2 Nantong Xinhe Biotechnology Business Overview
11.15.3 Nantong Xinhe Biotechnology Dactinomycin Introduction
11.15.4 Nantong Xinhe Biotechnology Revenue in Dactinomycin Business (2019-2024)
11.15.5 Nantong Xinhe Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Dactinomycin Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Injection
Table 3. Key Players of Implants
Table 4. Global Dactinomycin Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Dactinomycin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Dactinomycin Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Dactinomycin Market Share by Region (2019-2024)
Table 8. Global Dactinomycin Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Dactinomycin Market Share by Region (2025-2030)
Table 10. Dactinomycin Market Trends
Table 11. Dactinomycin Market Drivers
Table 12. Dactinomycin Market Challenges
Table 13. Dactinomycin Market Restraints
Table 14. Global Dactinomycin Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Dactinomycin Market Share by Players (2019-2024)
Table 16. Global Top Dactinomycin Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dactinomycin as of 2023)
Table 17. Ranking of Global Top Dactinomycin Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Dactinomycin Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Dactinomycin Product Solution and Service
Table 21. Date of Enter into Dactinomycin Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Dactinomycin Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Dactinomycin Revenue Market Share by Type (2019-2024)
Table 25. Global Dactinomycin Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Dactinomycin Revenue Market Share by Type (2025-2030)
Table 27. Global Dactinomycin Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Dactinomycin Revenue Market Share by Application (2019-2024)
Table 29. Global Dactinomycin Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Dactinomycin Revenue Market Share by Application (2025-2030)
Table 31. North America Dactinomycin Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Dactinomycin Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Dactinomycin Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Dactinomycin Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Dactinomycin Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Dactinomycin Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Dactinomycin Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Dactinomycin Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Dactinomycin Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Dactinomycin Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Dactinomycin Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Dactinomycin Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Dactinomycin Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Dactinomycin Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Dactinomycin Market Size by Country (2025-2030) & (US$ Million)
Table 46. AstraZeneca Company Detail
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca Dactinomycin Product
Table 49. AstraZeneca Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. GSK Company Detail
Table 52. GSK Business Overview
Table 53. GSK Dactinomycin Product
Table 54. GSK Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 55. GSK Recent Development
Table 56. Recordati Rare Diseases Company Detail
Table 57. Recordati Rare Diseases Business Overview
Table 58. Recordati Rare Diseases Dactinomycin Product
Table 59. Recordati Rare Diseases Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 60. Recordati Rare Diseases Recent Development
Table 61. Lundbeck Company Detail
Table 62. Lundbeck Business Overview
Table 63. Lundbeck Dactinomycin Product
Table 64. Lundbeck Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 65. Lundbeck Recent Development
Table 66. Merck Company Detail
Table 67. Merck Business Overview
Table 68. Merck Dactinomycin Product
Table 69. Merck Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 70. Merck Recent Development
Table 71. Prasco Laboratories Company Detail
Table 72. Prasco Laboratories Business Overview
Table 73. Prasco Laboratories Dactinomycin Product
Table 74. Prasco Laboratories Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 75. Prasco Laboratories Recent Development
Table 76. X-GEN Pharmaceuticals Company Detail
Table 77. X-GEN Pharmaceuticals Business Overview
Table 78. X-GEN Pharmaceuticals Dactinomycin Product
Table 79. X-GEN Pharmaceuticals Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 80. X-GEN Pharmaceuticals Recent Development
Table 81. Mylan Institutional Company Detail
Table 82. Mylan Institutional Business Overview
Table 83. Mylan Institutional Dactinomycin Product
Table 84. Mylan Institutional Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 85. Mylan Institutional Recent Development
Table 86. Bedford Pharmaceuticals Company Detail
Table 87. Bedford Pharmaceuticals Business Overview
Table 88. Bedford Pharmaceuticals Dactinomycin Product
Table 89. Bedford Pharmaceuticals Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 90. Bedford Pharmaceuticals Recent Development
Table 91. HISUN Company Detail
Table 92. HISUN Business Overview
Table 93. HISUN Dactinomycin Product
Table 94. HISUN Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 95. HISUN Recent Development
Table 96. Hainan Jinrui Pharmaceutical Company Detail
Table 97. Hainan Jinrui Pharmaceutical Business Overview
Table 98. Hainan Jinrui Pharmaceutical Dactinomycin Product
Table 99. Hainan Jinrui Pharmaceutical Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 100. Hainan Jinrui Pharmaceutical Recent Development
Table 101. Qilu Pharmaceutical Company Detail
Table 102. Qilu Pharmaceutical Business Overview
Table 103. Qilu Pharmaceutical Dactinomycin Product
Table 104. Qilu Pharmaceutical Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 105. Qilu Pharmaceutical Recent Development
Table 106. Shanghai Zhongke Pharmaceutical Company Detail
Table 107. Shanghai Zhongke Pharmaceutical Business Overview
Table 108. Shanghai Zhongke Pharmaceutical Dactinomycin Product
Table 109. Shanghai Zhongke Pharmaceutical Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 110. Shanghai Zhongke Pharmaceutical Recent Development
Table 111. Shanghai Xinya Pharmaceutical Company Detail
Table 112. Shanghai Xinya Pharmaceutical Business Overview
Table 113. Shanghai Xinya Pharmaceutical Dactinomycin Product
Table 114. Shanghai Xinya Pharmaceutical Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 115. Shanghai Xinya Pharmaceutical Recent Development
Table 116. Nantong Xinhe Biotechnology Company Detail
Table 117. Nantong Xinhe Biotechnology Business Overview
Table 118. Nantong Xinhe Biotechnology Dactinomycin Product
Table 119. Nantong Xinhe Biotechnology Revenue in Dactinomycin Business (2019-2024) & (US$ Million)
Table 120. Nantong Xinhe Biotechnology Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dactinomycin Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Dactinomycin Market Share by Type: 2023 VS 2030
Figure 3. Injection Features
Figure 4. Implants Features
Figure 5. Global Dactinomycin Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Dactinomycin Market Share by Application: 2023 VS 2030
Figure 7. Alkylating Agent Case Studies
Figure 8. Hormone Case Studies
Figure 9. Plant Medicine Case Studies
Figure 10. Dactinomycin Report Years Considered
Figure 11. Global Dactinomycin Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Dactinomycin Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Dactinomycin Market Share by Region: 2023 VS 2030
Figure 14. Global Dactinomycin Market Share by Players in 2023
Figure 15. Global Top Dactinomycin Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dactinomycin as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Dactinomycin Revenue in 2023
Figure 17. North America Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Dactinomycin Market Share by Country (2019-2030)
Figure 19. United States Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Dactinomycin Market Share by Country (2019-2030)
Figure 23. Germany Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Dactinomycin Market Share by Region (2019-2030)
Figure 31. China Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Dactinomycin Market Share by Country (2019-2030)
Figure 39. Mexico Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Dactinomycin Market Share by Country (2019-2030)
Figure 43. Turkey Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Dactinomycin Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. AstraZeneca Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 46. GSK Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 47. Recordati Rare Diseases Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 48. Lundbeck Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 49. Merck Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 50. Prasco Laboratories Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 51. X-GEN Pharmaceuticals Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 52. Mylan Institutional Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 53. Bedford Pharmaceuticals Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 54. HISUN Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 55. Hainan Jinrui Pharmaceutical Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 56. Qilu Pharmaceutical Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 57. Shanghai Zhongke Pharmaceutical Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 58. Shanghai Xinya Pharmaceutical Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 59. Nantong Xinhe Biotechnology Revenue Growth Rate in Dactinomycin Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
